Key result
Higher baseline heart rate variability significantly and inversely predicted prostate-specific antigen levels at 6 months in prostate cancer patients, independent of confounders (r=-0.434, p=0.004).
Why the study?
Does heart rate variability predict clinical outcomes in prostate and non-small cell lung cancer patients?
Population
246 patients, comprising 113 with prostate cancer (PC) and 133 with non-small cell lung cancer (NSCLC)
Design
Cohort
Follow-up
6 and 24 months for PC; not explicitly stated for NSCLC
Authors
Loading...
May inform prognostication in prostate cancer; hypothesis-generating and should not yet change practice.
Cohort (n=246)
No
Does heart rate variability predict clinical outcomes in prostate and non-small cell lung cancer patients?
Effect estimate: r=-0.434
p-value: p=0.004
Heart rate variability, an index of vagal nerve activity, may have a prognostic role in prostate cancer and in younger patients with non-small cell lung cancer.
Couck et al. (2013) conducted a cohort in Prostate cancer and non-small cell lung cancer (n=246). Heart rate variability (vagal nerve activity) vs. Lower heart rate variability was evaluated on Prostate-specific antigen (PSA) levels at 6 months in prostate cancer patients (r=-0.434, p=0.004). Higher baseline heart rate variability significantly and inversely predicted prostate-specific antigen levels at 6 months in prostate cancer patients, independent of confounders (r=-0.434, p=0.004).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: